home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Masimo Corporation - Common Stock (NQ:MASI)

132.76 -0.52 (-0.39%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Masimo Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

How Is The Market Feeling About Masimo? ↗

March 25, 2025

Via Benzinga

Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

March 21, 2025

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

Via StockStory

Topics Artificial Intelligence

$1000 Invested In Masimo 15 Years Ago Would Be Worth This Much Today ↗

March 19, 2025

Via Benzinga

Masimo (MASI): Buy, Sell, or Hold Post Q4 Earnings?

March 17, 2025

What a fantastic six months it’s been for Masimo. Shares of the company have skyrocketed 45.8%, hitting $167.70. This was partly due to its solid quarterly results, and the run-up might have investors...

Via StockStory

3 Small-Cap Stocks in Hot Water

March 13, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗

March 07, 2025

Via Benzinga

Masimo Makes A Bullish Post-Earnings Move. Why One Analyst Is Cautious. ↗

February 26, 2025

Future earnings growth could falter as Masimo makes steep cost reductions.

Via Investor's Business Daily

Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)

March 11, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest...

Via StockStory

Topics Artificial Intelligence

Xpeng, Li Auto And Nutanix Are Among Top 12 Large-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio? ↗

March 02, 2025

These large-cap stocks were top performers last week. Heico, Xpeng, Li Auto, Lineage, Erie Indemnity, Lloyds, Unum, FICO, Masimo, Smith & Nephew, AB InBev, and Nutanix all saw significant gains.

Via Benzinga

Masimo to Present in the 46th Annual Raymond James Institutional Investor Conference

February 28, 2025

From Masimo

Via Business Wire

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

Price Over Earnings Overview: Masimo ↗

February 19, 2025

Via Benzinga

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today ↗

February 14, 2025

Via Benzinga

(MASI) - Analyzing Masimo's Short Interest ↗

February 12, 2025

Via Benzinga

Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)

February 27, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom...

Via StockStory

Topics Artificial Intelligence

Why Is Masimo (MASI) Stock Soaring Today

February 26, 2025

Shares of medical tech company Masimo (NASDAQ:MASI) jumped 11.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which beat analysts' revenue and EPS...

Via StockStory

Masimo Tops EPS, Revenue Expectations ↗

February 25, 2025

Masimo impressed with a robust earnings report driven by its healthcare segment, despite challenges from non-healthcare operations.

Via The Motley Fool

Masimo (NASDAQ:MASI) Posts Better-Than-Expected Sales In Q4

February 25, 2025

Medical tech company Masimo (NASDAQ:MASI) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.4% year on year to $600.7 million. Its non-GAAP profit of $1.80 per share...

Via StockStory

Deep Dive Into Masimo Stock: Analyst Perspectives (7 Ratings) ↗

January 22, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

January 14, 2025

Via Benzinga

$1000 Invested In Masimo 15 Years Ago Would Be Worth This Much Today ↗

January 07, 2025

Via Benzinga

Masimo Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Updated Full-Year 2025 Guidance

February 25, 2025

From Masimo

Via Business Wire

Earnings To Watch: Masimo (MASI) Reports Q4 Results Tomorrow

February 24, 2025

Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Via StockStory

Masimo Announces Leadership Transition

January 21, 2025

From Masimo

Via Business Wire

Masimo Announces Select Preliminary 2024 Financial Results and 2025 Guidance

January 16, 2025

From Masimo Corporation

Via Business Wire

What Analysts Are Saying About Masimo Stock ↗

December 27, 2024

Via Benzinga

The Law Offices of Frank R. Cruz Announces Investigation of Masimo Corporation (MASI) on Behalf of Investors

January 14, 2025

From Law Offices of Frank R. Cruz

Via Business Wire

Masimo to Present in the 43rd Annual J.P. Morgan Healthcare Conference

January 08, 2025

From Masimo

Via Business Wire

MASIMO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Masimo Corporation - MASI

January 03, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday ↗

December 27, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com